<DOC>
	<DOCNO>NCT02212379</DOCNO>
	<brief_summary>This multicenter , international , non randomize ( single arm ) , open , phase II trial aim evaluate capacity dual combination raltegravir/etravirine maintain virological success virologically suppress HIV-1 infected patient , least 45 year age , switch boost PI-containing regimen . Patients follow 96 week . Measurement primary endpoint 48 week . Virological success define absence 2 consecutive plasma viral load &gt; 50 copies/mL within 2 4 week dual raltegravir/etravirin regimen . Raltegravir/etravirine consider acceptable percentage patient virological success week 48 significantly 90 % . Assuming 95 % virological success rate , include 160 individual consider strategy acceptable 8 individual virological failure ; investigator 95 % probability discard combination efficacy small 90 % investigator select power 80 % strategy efficacy equal 95 % . The principal secondary endpoint proportion patient therapeutic success week 48 96 .</brief_summary>
	<brief_title>Capacity Dual Combination Raltegravir/Etravirine Maintain Virological Success HIV-1 Infected Patients Least 45 Years Age- ANRS 163 ETRAL</brief_title>
	<detailed_description />
	<mesh_term>Etravirine</mesh_term>
	<mesh_term>Raltegravir Potassium</mesh_term>
	<criteria>Documented HIV1 infection Age ≥ 45 year Naïve integrase inhibitor etravirine At least 6 month stable antiretroviral therapy ( ART ) include boost protease inhibitor , whatever number combine drug HIVRNA plasma VL ≤ 50 copies/mL last 24 month prior screen visit ( Week6/Week4 ) , document least 4 timepoints one blip HIVRNA plasma viral load 51 200 copies/mL HIVRNA plasma VL ≤ 50 copies/mL screen visit ( Week6/Week4 ) A genotype available ( amplified DNA Week6/Week4 Visit and/or RNA medical history patient ) show virus sensitive ETR OR genotype available ( amplification failure DNA Week6/Week4 Visit genotype medical history patient ) , virological failure NNRTI medical history CD4+ lymphocytes &gt; 200 cells/mm3 Creatinine &lt; 2.5 x ULN CPK ( Creatine Phospho Kinase ) &lt; 6 ULN ( Upper Limit Normal ) AST ( Aspartate Aminotransferase ) , ALT ( Alanine Aminotransferase ) &lt; 5 ULN Hemoglobin &gt; 10 g/dL Platelets &gt; 100 000/mm3 Negative urinary pregnancy test use efficient contraception woman childbearing potential For French participant : subject enrol beneficiary Social Security programme ( State Medical Aid AME Social Security programme ) , article L112111 Public heatlh code Patients coverage social health Signed inform consent Previous exposure raltegravir etravirine Presence document integrase inhibitor mutation DNA genotype Week6/Week4 and/or RNA medical history patient Positive hepatitis B HBsAg Positive HBc Ac negative HBs Ac HIV2 infection Active viral hepatitis C require specific treatment 24 month trial Patient history noncompliance irregular followup Initiation concomitant antihypercholesterolemia ( e.g . statin ) antidiabetic treatment within last 3 month prior screen visit ( Week6 /Week4 ) Patient use : Clopidogrel ( Plavix® ) , Prasugrel ( Effient® ) , Ticagrelor ( Brilinta® ) , Ticlopidine ( Ticlid® ) , Flurbiprofen ( Antadys® Cebutid® ) , Rifampin ( Rifampicin® Rifadin® RofactMC Rifater® ) , Rifapentine ( Priftin® ) , St John 's wort , Carbamazepine ( Tegretol® ) , Phenobarbital , Phenytoin ( Dilantin® ) , Avanafil ( Stendra™ ) , Triazolam ( Halcion® ) Concomitant treatment use interferon , interleukins immunetherapy chemotherapy Concomitant prophylactic curative treatment opportunistic infection All condition ( use alcohol , drug , etc . ) judge investigator possibly interfere trial protocol compliance , adherence and/or trial treatment tolerance Subjects `` sauvegarde de justice '' ( judicial protection due temporarily slightly diminish mental physical faculty ) , legal guardianship Subjects participate another clinical trial evaluate different therapy include exclusion period still force screen phase Pregnant woman breastfeed woman</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Raltegravir</keyword>
	<keyword>Etravirine</keyword>
	<keyword>age , 45</keyword>
	<keyword>Viral load</keyword>
	<keyword>Efficacy</keyword>
	<keyword>Safety</keyword>
</DOC>